170 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
, 2022
Assets
Current assets:
Cash
Restricted cash
Tax credit receivable
Prepaid expenses and other current assets
Total current assets
Property
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
(unaudited)
Assets
Current assets:
Cash
Restricted cash
Tax credit receivable
Prepaid expenses and other current assets
Total current assets
Property
8-K
EX-99.1
zq45zxdtz6a4ixc86mf
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
424B5
4tvuv3ikylqhbz46h4ds
15 Jun 23
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
gjdaqkr7pwskdtdp6
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-10.1
g06bu2uqsingb02nj1u
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am